参考文献/References:
[1] Sa?d-Sadier N, Ojcius DM. Alarmins, inflammasomes and immunity. BiomedJ, 2012, 35(6):437-449.
[2] Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity:update on Toll-like receptors. Nat Immunol, 2010, 11(5):373-384.
[3] Candido J, Hagemann T. Cancer-related inflammation. J Clin Immunol, 2013, 33 Suppl 1:S79-84.
[4] Woods DC, White YA,Dau C, et al. TLR4 activates NF-кB in human ovarian granulosa tumor cells. Biochem Biophys Res Commun, 2011, 409(4):675-680.
[5] Sato Y, Goto Y, Narita N, et al. Cancer cells expressing Toll-like receptors and the tumor microenvironment. Cancer Microenviron, 2009,2 Supplel:S205-214.
[6] Kelly MG, Alvero AB, Chen R, et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res, 2006, 66(7):3859-3868.
[7] Rakoff-Nahoum S, Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer, 2009,9(1):57-63.
[8] Mittal D, Saccheri F, Vénéreau E, et al. TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. EMBO J, 2010, 29(13):2242-2252.
[9] Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homo-logue of the Drosophila Toll protein signals activation of adaptive immunity. Nature, 1997, 388(6640):394-397.
[10] Gurung P, Malireddi RK, Anand PK, et al. Toll or interleukin-1 receptor (TIR) domain-containing adaptor inducing interferon-(β(TRIF)-mediated caspase-11 protease production integrates Tolllike receptor 4(TLR4) protein-and Nlrp3 inflammasome-mediated host defense against enteropathogens. J Biol Chem, 2012,287(41):34474-34483.
[11] Jin B,Sun T,Yu XH,et al. The effects of TLR activation on T-cell development and differentiation[J/OL]. Clin Dev Immunol,2012,2012:El[2013-05-15]. http://www.hindawi.com/joumals/cdi/2012/836485.[published online ahead of print Jun 7,2012].
[12] Bauer S,Müller T,Hamm S. Pattern recognition by Toll-like receptors. Adv Exp Med Biol,2009,653(1):15-34.
[13] Kumar H,Kawai T,Akira S. Toll-like receptors and innate immunity. Biochem Biophys Res Commun,2009,388(4):621-625.
[14] Huang B,Zhao J,Unkeless JC,et al. TLR signaling by tumor and immune cells:a double-edged sword. Oncogene,2008,27(2):218-224.
[15] Andreani V,Gatti G,Simonella L,et al. Activation of Toll-like receptor 4 on tumor cells in vitro inhibits subsequent tumor growth in vivo. Cancer Res,2007,67(21):10519-10527.
[16] Wolska A,Lech-Marańda E,Robak T. Toll-like receptors and their role in carcinogenesis and anti-tumor treatment. Cell Mol Biol Lett,2009,14(2):248-272.
[17] Gambara G,De Cesaris P,De Nunzio C,et al. Toll-like receptors in prostate infection and cancer between bench and bedside. J Cell Mol Med,2013,17(6):713-722.
[18] Huang B,Zhao J,Li H,et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res,2005,65(12):5009-5014.
[19] Yang H,Zhou H,Feng P,et al. Reduced expression of Toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion. J Exp Clin Cancer Res,2010,29:92.
[20] Chochi K,Ichikura T,Kinoshita M. et al. Helicobacter pylori augments growth of gastric cancers via the lipopolysaccharide-toll-like receptor 4 pathway whereas its lipopolysaccharide attenuates anti-tumor activities of human mononuclear cells. Clin Cancer Res,2008,14(10):2909-2917.
[21] Wild CA,Bergmann C,Fritz G,et al. HMGB1 conveys immunosup-pressive characteristics on regulatory and conventional T cells. Int Immunol,2012,24(8):485-494.
[22] Del Prete A,Allavena P,Santoro G,et al. Molecular pathways in cancer-related inflanunation. Biochem Med (Zagreb),2011,21(3):264-275.
[23] Luo Y,Chihara Y,Fujimoto K,et al. High mobility group box 1 released from necrotic cells enhances regrowth and metastasis of cancer cells that have survived chemotherapy. Eur J Cancer,2013,49(3):741-751.
[24] Riddell JR,Bshara W,Moser M T,et al. Peroxiredoxin 1 controls prostate cancer growth through Toll-like receptor 4-dependent regulation of tumor vasculature. Cancer Res,2011,71(5):1637-1646.
[25] Johnson GB,Brunn GJ,Platt JL. Cutting edge:an endogenous pathway to systemic in flammatory response syndrome (SIRS)-likereactions through Toll-like receptor 4. J Immunol,2004,172(1):20-24.
[26] Wang L,Zhao Y,Qian J,et al. Toll-like receptor-4 signaling in mantle cell lymphoma:effects on tumor growth and immune evasion. Cancer,2013,119(4):782-791.
[27] Apetoh L,Tesniere A,Ghiringhelli F,et al. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anti cancer therapies. Cancer Res,2008,68(11):4026-4030.
[28] Hua D,Liu MY,Cheng ZD,et al. Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion,survival and tumorigenicity. Mol Immunol,2009,46(15):2876-2884.
[29] Tang X,Zhu Y. TLR4 signaling promotes immune escape of human colon cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Oncol Res,2012,20(1):15-24.
[30] Sun Z,Luo Q,Ye D,et al. Role of toll-like receptor 4 on the immune escape of human oral squamous cell carcinoma and resistance of cisplatin-induced apoptosis. Mol Cancer,2012,11:33.
[31] Szajnik M,Szczepanski MJ,Czystowska M,et al. TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene,2009,28(49):4353-4363.
[32] Apetoh L,Ghiringhelli F,Tesniere A,et al. Toll-like receptor 4-dependent contribution of the immune system to anti cancer chemotherapy and radiotherapy. Nat Med,2007,13(9):1050-1059.
[33] 卢良杰,董娟聪,张聪,等. Toll样受体4对肿瘤细胞放射敏感性的影响. 中华放射医学与防护杂志,2012,32(6):583-587.
[34] Cao N,Li S,Wang Z,et al. NF-кB-mediated HER2 overexpression in radiation-adaptive resistance. Radiat Res,2009,171(1):9-21.
[35] Multhoff G,Radons J. Radiation,inflammation,and immuneresponses in cancer[J/OL]. Front Oncol,2012,2:El[2013-05-15]. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3366472.[published online ahead of print Jun 4,2012].
[36] Galluzzi L,Vacchelli E,Eggermont A,et al. Trial Watch:Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology,2012,1(5):699-716.
相似文献/References:
[1]何燕,苏晋,郑晓霞,等.P-糖蛋白抑制剂在PET显像中的应用研究[J].国际放射医学核医学杂志,2016,40(1):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
He Yan,Su Jin,ZhengXiaoxia,et al.Developing P-glycoprotein inhibitor marked by PET[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
[2]许飞,刘建军,黄钢,等.PET乏氧显像在预测肿瘤乏氧及指导临床治疗中的应用进展[J].国际放射医学核医学杂志,2016,40(1):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
Xu Fei,Liu Jianjun,Huang Gang,et al.The application of hypoxia imaging with PET in predicting tumor hypoxia and guiding clinical therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
[3]陈顺军,程兵.肿瘤细胞凋亡核素显像分子探针研究进展[J].国际放射医学核医学杂志,2016,40(2):149.[doi:10.3760/cma.j.issn.1673-4114.2016.02.013]
Chen Shunjun,Cheng Bing.Progress in molecular probes of radionuclide tumor apoptosis imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):149.[doi:10.3760/cma.j.issn.1673-4114.2016.02.013]
[4]陈晓艳,张江虹,邵春林.STAT3与辐射敏感相关性的研究进展[J].国际放射医学核医学杂志,2016,40(3):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
Chen Xiaoyan,Jianghong,Shao Chunlin.Research progresses of correlation between STAT3 and radiosensitivity[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
[5]赵舒怡,储小飞,樊赛军.血清肿瘤标志物与肿瘤放疗疗效评估的研究进展[J].国际放射医学核医学杂志,2015,39(5):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
zhao shuyi,chu xiaofei,fan saijun..progression of study on serum tumor markers in evaluation of tumor radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
[6]赵徵鑫,翟贺争,张文艺,等.质子重离子治疗肿瘤的进展[J].国际放射医学核医学杂志,2016,40(5):384.[doi:10.3760/cma.j.issn.1673-4114.2016.05.010]
Zhao Zhixin,Zhai Hezheng,Zhang Wenyi,et al.Development of proton heavy ion in tumor therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):384.[doi:10.3760/cma.j.issn.1673-4114.2016.05.010]
[7]任佳忠,李永梅,刘岩,等.99Tcm-MDP骨显像胸部异常放射性摄取的原因分析[J].国际放射医学核医学杂志,2016,40(6):459.[doi:10.3760/cma.j.issn.1673-4114.2016.06.011]
Jiazhong,Li Yongmei,Liu Yan,et al.Reasons for the abnormal 99Tcm-MDP uptake in the thoracic tissue on bone scintigraphy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):459.[doi:10.3760/cma.j.issn.1673-4114.2016.06.011]
[8]马彦云,张辉.磁共振体素内不相干运动扩散加权成像的原理及应用进展[J].国际放射医学核医学杂志,2016,40(6):469.[doi:10.3760/cma.j.issn.1673-4114.2016.06.013]
Ma Yanyun,Zhang Hui.The basic principle and application progress of intravoxel incoherent motion imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):469.[doi:10.3760/cma.j.issn.1673-4114.2016.06.013]
[9]杨卫东,汪静.肿瘤核素靶向治疗新进展[J].国际放射医学核医学杂志,2015,39(1):19.[doi:10.3760/cma.j.issn.1673-4114.2015.01.006]
Yang Weidong,Wang Jing.Advance progress of radionuclide target tumor therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):19.[doi:10.3760/cma.j.issn.1673-4114.2015.01.006]
[10]徐金苹,袁德晓,张江虹,等.辐射诱导的外泌体在肿瘤细胞侵袭转移中的作用[J].国际放射医学核医学杂志,2015,39(2):144.[doi:10.3760/cma.j.issn.1673-4114.2015.02.009]
Xu Jinping,Yuan Dexiao,Zhang Jianghong,et al.The role of radiation-induced exosomes in tumor invasion and metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):144.[doi:10.3760/cma.j.issn.1673-4114.2015.02.009]